The nation’s largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers. Express Scripts says it will no longer cover Sovaldi and Harvoni from Gilead Sciences or Johnson & Johnson’s Olysio starting Jan. 1, except under limited circumstances.

Click here to read original article